Skip to main content

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Publication ,  Journal Article
Yacoub, A; Mascarenhas, J; Kosiorek, H; Prchal, JT; Berenzon, D; Baer, MR; Ritchie, E; Silver, RT; Kessler, C; Winton, E; Finazzi, MC; Mesa, R ...
Published in: Blood
October 31, 2019

Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To further define the role of rIFN-α, we investigated the outcomes of pegylated-rIFN-α2a (PEG) therapy in ET and PV patients previously treated with hydroxyurea (HU). The Myeloproliferative Disorders Research Consortium (MPD-RC)-111 study was an investigator-initiated, international, multicenter, phase 2 trial evaluating the ability of PEG therapy to induce complete (CR) and partial (PR) hematologic responses in patients with high-risk ET or PV who were either refractory or intolerant to HU. The study included 65 patients with ET and 50 patients with PV. The overall response rates (ORRs; CR/PR) at 12 months were 69.2% (43.1% and 26.2%) in ET patients and 60% (22% and 38%) in PV patients. CR rates were higher in CALR-mutated ET patients (56.5% vs 28.0%; P = .01), compared with those in subjects lacking a CALR mutation. The median absolute reduction in JAK2V617F variant allele fraction was -6% (range, -84% to 47%) in patients achieving a CR vs +4% (range, -18% to 56%) in patients with PR or nonresponse (NR). Therapy was associated with a significant rate of adverse events (AEs); most were manageable, and PEG discontinuation related to AEs occurred in only 13.9% of subjects. We conclude that PEG is an effective therapy for patients with ET or PV who were previously refractory and/or intolerant of HU. This trial was registered at www.clinicaltrials.gov as #NCT01259856.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

October 31, 2019

Volume

134

Issue

18

Start / End Page

1498 / 1509

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Thrombocythemia, Essential
  • Recombinant Proteins
  • Polyethylene Glycols
  • Polycythemia Vera
  • Middle Aged
  • Male
  • Interferon-alpha
  • Immunology
  • Hydroxyurea
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yacoub, A., Mascarenhas, J., Kosiorek, H., Prchal, J. T., Berenzon, D., Baer, M. R., … Hoffman, R. (2019). Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 134(18), 1498–1509. https://doi.org/10.1182/blood.2019000428
Yacoub, Abdulraheem, John Mascarenhas, Heidi Kosiorek, Josef T. Prchal, Dmitry Berenzon, Maria R. Baer, Ellen Ritchie, et al. “Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.Blood 134, no. 18 (October 31, 2019): 1498–1509. https://doi.org/10.1182/blood.2019000428.
Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019 Oct 31;134(18):1498–509.
Yacoub, Abdulraheem, et al. “Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.Blood, vol. 134, no. 18, Oct. 2019, pp. 1498–509. Pubmed, doi:10.1182/blood.2019000428.
Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019 Oct 31;134(18):1498–1509.

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

October 31, 2019

Volume

134

Issue

18

Start / End Page

1498 / 1509

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Thrombocythemia, Essential
  • Recombinant Proteins
  • Polyethylene Glycols
  • Polycythemia Vera
  • Middle Aged
  • Male
  • Interferon-alpha
  • Immunology
  • Hydroxyurea